YKST02
/ Excyte
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 28, 2024
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: Excyte Biopharma Ltd
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1